Rhobust® is able to fractionate plasma proteins at industrial scale and is ideally placed to become the method of choice for processing therapeutics from blood plasma. The market demand for intravenous immunoglobulin (IVIG) is increasing. IVIG is extracted from human plasma supplies and Rhobust® platform enables this extraction process to be simplified by eliminating filtration steps and employing specific adsorbents that reduce the number of purification steps, thereby increasing IVIG yields.

UpFront’s Rhobust® platform simplifies processes by eliminating filtration steps and employing specific immunoglobulin-binding adsorbents that reduce the number of purification steps. As each process manipulation decreases overall yield, Rhobust® has the effect of increasing plasma yields by up to1-2g/L.

More

Example of Human Plasma Fractionation Using EBA